A nonbiologic oral IL-23 inhibitor is more effective and safer than an approved oral JAK inhibitor for moderate-to-severe ...

Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), today announces it will advance its second asset, a fully human anti-IL-6 receptor (“IL-6R”) monoclonal antibody, TZLS-501.

Greek yogurt supplementation post-training significantly reduces inflammation markers in young males, offering insights into ...

Neuroinflammation is linked to a host of detrimental brain disorders, including Alzheimer's and Parkinson's disease. A ...

The latest announcement is out from Tiziana Life Sciences ( (TLSA) ).

Neuroinflammation is linked to a host of detrimental brain disorders, including Alzheimer's and Parkinson's disease. A ...

Tiziana Life Sciences (TLSA) will advance its second asset, a fully human anti-IL-6 receptor monoclonal antibody, TZLS-501. Tiziana will pursue ...

The protein on human cells that tick-borne encephalitis virus (TBEV) uses for infection has now been identified—a major step toward understanding how TBEV causes neurological disease and for ...

Bernstein 2nd Annual Global Healthcare Conference September 23, 2025 1:58 PM EDTCompany ParticipantsMatthew Gline - ...

Explore how machine learning is revolutionising interstitial lung disease management, enhancing early diagnosis, treatment, ...

Bernstein 2nd Annual Global Healthcare Conference September 24, 2025 1:10 PM EDTCompany ParticipantsTom Cavanaugh - ...